Mumbai, April 25, 2025: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, launches its new cutting-edge Elevate Platform upgrade release on the EPIQ Elite ultrasound imaging platform, at UltraFest 2025 in India. This pioneering solution addresses the increasing demand for streamlined workflows and greater diagnostic efficiency, enabling clinicians to deliver timely, confident decisions for a wider range of patients. Information, estimates, expectations and business plans in this press-release may include forward-looking statements for knowledge sharing purposes and not intended to provide medical advice, diagnosis, or treatment suggestions. All information provided by or on behalf of Philips (or any of its affiliates) is provided on an “as is, where is” basis, and no representation or warranty, express or implied, regarding the accurateness or correctness thereof is assumed by Philips in any manner. The technical operation of the medical device should be under the supervision of a physician/doctor, and we do not solicit/ promote self-administration of the said medical device without the supervision of physician/doctor. Philips shall not be liable for any damages arising from the contents including but not limited to direct, indirect, incidental, punitive and consequential damages. *Source: Based on comparative studies on previous EPIQ model.
Elevate platform is equipped with advanced Artificial Intelligence capabilities which have proven instrumental in enhancing diagnostic accuracy and operational efficiency. The platform also incorporates proactive system monitoring, allowing care teams to consult remotely, support diagnosis from a distance, and troubleshoot systems without the need for on-site intervention.
Sachin Grover, Head of Ultrasound, Philips Indian Subcontinent commented “We’re proud to introduce our latest AI-enabled innovation, the Elevate platform upgrade on the EPIQ Elite ultrasound platform, here in the Indian Subcontinent. Philips has a rich legacy of delivering intelligent workflow solutions that enhance diagnostic confidence and drive better patient outcomes. Elevate is a powerful example of our commitment to helping healthcare providers address today’s urgent challenges—from rising patient volumes to workforce constraints. With smarter automation, faster diagnostics, and greater clinical precision, we’re enabling clinicians to deliver high-quality care more efficiently. At Philips, we firmly believe in the transformative potential of Artificial Intelligence to make healthcare more effective, accessible, and inclusive bringing us closer to a future where we provide better care for more people.”
The latest suite of automation features includes Quick Launch pre-sets to streamline platform setup and routine procedures, reducing imaging optimization time*. Other features include automatic adjustment of image brightness and uniformity, as well as CEUS AutoScan, which improves image quality by fine-tuning each pixel and frame. For liver elastography, the system offers Auto ElastQ, which helps measure liver stiffness more easily and quickly, providing a simple, non-invasive way to assess liver health.
DISCLAIMER
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.